Cargando…

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

BACKGROUND: The benefit of immune checkpoint inhibitors (ICIs) in patients with leptomeningeal metastases (LMM) is unknown. METHODS: We undertook a phase II trial of pembrolizumab in patients with LMM from solid tumors. Eligible patients had radiologic/cytologic LMM and Eastern Cooperative Oncology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naidoo, Jarushka, Schreck, Karisa C, Fu, Wei, Hu, Chen, Carvajal-Gonzalez, Alexander, Connolly, Roisin M, Santa-Maria, Cesar A, Lipson, Evan J, Holdhoff, Matthias, Forde, Patrick M, Douville, Christopher, Riemer, Joanne, Barnes, Amanda, Redmond, Kristin J, Kleinberg, Lawrence, Page, Brandi, Aygun, Nafi, Kinzler, Kenneth W, Papadopoulos, Nickolas, Bettegowda, Chetan, Venkatesan, Arun, Brahmer, Julie R, Grossman, Stuart A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359453/ https://www.ncbi.nlm.nih.gov/pubmed/34380662 http://dx.doi.org/10.1136/jitc-2021-002473

Ejemplares similares

2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors
por: Naidoo, Jarushka, et al.
Publicado: (2018)

Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
por: Schreck, Karisa C., et al.
Publicado: (2019)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
por: Wills, Beatriz, et al.
Publicado: (2018)

RADI-23. Exploring the optimal timing of routine initial surveillance MRI following treatment of brain metastases with stereotactic radiosurgery: a comparison of two approaches
por: Lin, Timothy, et al.
Publicado: (2021)

Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells
por: Xia, Yuanxuan, et al.
Publicado: (2018)

RADI-22. Toxicity and local control outcomes for brain metastases managed with resection and aggressive reirradiation after initial radiosurgery failure
por: Bhatia, Rohini, et al.
Publicado: (2021)

Management and Molecular Characterization of Intraventricular Glioblastoma: A Single-Institution Case Series
por: Parker, Megan, et al.
Publicado: (2023)

Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
por: Douville, Christopher, et al.
Publicado: (2023)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Outcomes of Metastatic Brain Lesions Treated with Radioactive Cs-131 Seeds after Surgery: Experience from One Institution
por: Xia, Yuanxuan, et al.
Publicado: (2018)

A Dose-Response Model of Local Tumor Control Probability After Stereotactic Radiosurgery for Brain Metastases Resection Cavities
por: Gui, Chengcheng, et al.
Publicado: (2020)

Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy
por: Stachelek, Gregory C., et al.
Publicado: (2019)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022)

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

Current and Future Frontiers of Molecularly Defined Oligodendrogliomas
por: Rincon-Torroella, Jordina, et al.
Publicado: (2022)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
por: Naidoo, Jarushka, et al.
Publicado: (2017)

Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage
por: Shen, Colette J., et al.
Publicado: (2018)

A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab
por: Palacka, Patrik, et al.
Publicado: (2022)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
por: Moseley, Kendall F., et al.
Publicado: (2018)

Pembrolizumab-induced bullous pemphigoid
por: Sun, Christina W., et al.
Publicado: (2019)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
por: Cluxton, Christopher, et al.
Publicado: (2023)

Genetic landscape of extreme responders with anaplastic oligodendroglioma
por: Holdhoff, Matthias, et al.
Publicado: (2017)

Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study
por: Parker, Megan, et al.
Publicado: (2023)

Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors
por: Downs, Bradley M., et al.
Publicado: (2021)

Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients
por: Rincon-Torroella, Jordina, et al.
Publicado: (2021)

Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic radiosurgery for brain metastases
por: Peng, Luke, et al.
Publicado: (2019)

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

ECOA-10. Integrated genomic and clinical analysis of BRAF-mutated glioma in adults
por: Langat, Pinky, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ldg6fasut74l7qt4t1qmno5nm